A leaked version of a trade deal sparks alarm over access to drugs; CDC releases new opioid guidelines

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by     STAT+: A leaked version of a U.K.-India free trade deal sparks alarm over access to medicines By Ed Silverman Adobe There is concern the proposed deal would impede the supply of affordable generic medicines in poor countries around the world. Read More New CDC opioid guidelines emphasize flexibility in treating pain By Andrew Joseph Patrick Sison/AP The CDC drops some recommendations that had been interpreted too strictly, leaving some patients with uncontrolled pain. Read More Listen: How the biotech revolution could come apart at the seams By Damian Garde and Allison DeAngelis and Adam Feuerstein STAT's Matthew Herper joins us to discuss his story on how the biotech revolution could run aground if humanity can't get out of its own way. Read More Sponsored Insight by Kx Advisors Pre-commercial pharma and biotech companies face ever-increasing costs, complexities in drug launch As costs of developing new drugs grow, now more than ever, specialty pharmaceuticals must achieve immediate success following launch. However, developing a launch strategy for direct commercialization includes unique challenges for pre-revenue companies. With more than a third of all therapies failing to meet market expectations in the launch year, how do you define success for your commercial organization? What are the keys to an effective launch to establish a profitable trajectory? Find out here. STAT+: FDA approval decision for Apellis Pharma's eye disease drug delayed to review more clinical data By Adam Feuerstein Adobe The drug had already been mired in controversy because the FDA submission was based on clinical trials that produced confounding results. Read More Thursday, November 3, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser